Introduction {#sec1}
============

The metabolic enzyme isocitrate dehydrogenase 1 (IDH1) belongs to the family of IDHs, which catalyze the oxidative decarboxylation of isocitrate to α-ketoglutarate and reduce NAD(P)^+^ to NAD(P)H ([@ref47]). Missense mutations in the Arg132 residue of IDH1 have been found in a variety of human cancers, including glioma, acute myeloid leukemia, cartilaginous tumors, and intrahepatic cholangiocarcinoma ([@ref37]; [@ref18]; [@ref8]). The mutant IDH1 acquires a neomorphic enzyme activity, which converts α-ketoglutarate (α-KG) to 2-hydroxyglutarate (2-HG) ([@ref10]; [@ref54]; [@ref17]; [@ref30]; [@ref38]; [@ref48]). At superphysiological concentrations, the potential oncometabolite 2-HG inhibits α-KG-dependent dioxygenases resulting in global elevation of DNA and histone methylation, which likely promotes tumorigenesis ([@ref54]; [@ref13]; [@ref17]; [@ref30]; [@ref50]; [@ref28]; [@ref31]; [@ref33]; [@ref49]). However, the preclinical results with inhibitors of mutant IDH1 have been variable in different cancer models (e.g. glioma models) ([@ref5]; [@ref43]; [@ref47]). In addition, it has been reported that the high concentration of 2-HG produced by mutant IDH1/2 also has anti-tumor activity in glioma ([@ref44]). These observations reveal an unanticipated complexity of IDH1-related regulation in cancers and suggest that many of the functions of IDH1 still await identification and characterization.

RNA-binding proteins (RBPs) control all the steps in the life of an RNA, including fate determination, and functional modulation. RBPs participate in the regulation of multiple cellular processes at various layers, and their dysregulation is thought to be linked with numerous diseases, including neuropathies, muscular atrophies, metabolic disorders, and cancer ([@ref34]; [@ref9]; [@ref11]; [@ref16]). We have recently reported a novel role of IDH1 as an unconventional RBP based on a protein array-based RBP screen ([@ref32]). Profiling of the RNA targets of IDH1 in embryonic stem cells (ESCs) by an improved FLAG- and biotin-mediated tandem crosslinking and immunoprecipitation (CLIP) method, named ^FBio^CLIP-seq, revealed that IDH1 binds to thousands of RNA transcripts with enriched functions in transcription and chromatin regulation, the cell cycle, and RNA processing ([@ref32]). Interestingly, most of these genes are more likely to produce unstable mRNAs and proteins, based on global quantification of the abundance and turnover of the mammalian transcriptome and proteome ([@ref42]). In addition, native gel electrophoretic mobility shift assays indicated direct interactions between IDH1 and ssRNAs containing GA- or AU-rich, but not GC-rich, sequences. These results demonstrate direct and sequence-specific RNA-binding activity of IDH1 *in vivo* and *in vitro* ([@ref32]). However, the functional significance of IDH1's RNA-binding activity on posttranscriptional gene regulation remains elusive.

![Construction of IDH1 interactomes in various subcellular localizations. (**A**) Subcellular fractionation (cytoplasm, nucleoplasm, and chromatin) followed by western blotting. Tubulin, EZH2, and H3 are markers of cytoplasm, nucleus, and chromatin, respectively. Cyto, cytoplasm; Nuc, nucleoplasm; Chr, chromatin. (**B**) Scheme of TAP/MS for profiling IDH1 interactomes. (**C**) Heatmap summary of the results of IDH1 TAP/MS. RPS, ribosomal small subunit; RPL, ribosome large subunit; Regulator, the translational regulator. (**D**) Enriched GO terms in IDH1 interactomes (fold enrichment ≥1.5). (**E**) Graphical presentation of proteins involved in translation, protein folding, and metabolic process that interact with cytoplasmic IDH1.](mjz082f1){#f1}

In this study, we found that IDH1 associates with a large set of proteins involved in the process and regulation of translation. Knockout of IDH1 in ESCs led to subtle yet robustly detectable decreases in global translation. IDH1 directly promotes mRNA translation in a cap-dependent manner via reporter assays. Together, these results uncover an unexpected function of IDH1 as a translation modulator, which expands the current understanding of IDH1 and suggests a novel link between cellular metabolism and translation regulation.

Results {#sec2}
=======

Construction of IDH1 interactomes in various subcellular localizations {#sec3}
----------------------------------------------------------------------

To obtain a functional insight into IDH1, we sought to comprehensively profile proteins that interact with IDH1. As commercially available antibodies of IDH1 are not suitable for co-immunoprecipitation (coIP), we established ESC lines that stably express a subendogenous level of FLAG- and biotin-tagged IDH1 ([@ref32]). In addition, we also established a negative control ESC line that stably expresses FLAG- and biotin-tagged green fluorescent protein (GFP). Subcellular fraction analysis of IDH1 in ESCs showed that it is predominantly localized in the cytoplasm, but is also detected in the nucleoplasm and on the chromatin ([Figure 1A](#f1){ref-type="fig"}). Considering that protein subcellular localization often correlates with regulatory functions and interacting networks, we performed proteomic analysis after subcellular fractionation to get a more precise view of IDH1-bound interactomes in various subcellular localizations. We performed FLAG- and biotin-mediated tandem affinity purification followed by mass spectrometry (TAP/MS) on ESC lysates isolated from the cytosol, nucleoplasm, and chromatin fractions ([Figure 1B](#f1){ref-type="fig"}). To assess the degree of RNA-mediated protein--protein interactions in the IDH1 interactomes, we performed subcellular fractionation and TAP/MS analysis in the presence of RNase A in parallel, which can be regarded as an experimental replicate ([Figure 1B](#f1){ref-type="fig"}).

Using a cutoff of ≥10 for the maximal MS score of IDH1 and ≥5 for the ratio of MS scores of IDH1 vs. GFP (IDH1/GFP), TAP/MS identified a total of 285 proteins that specifically bind to IDH1 but not the control GFP protein ([Figure 1C](#f1){ref-type="fig"}; [Supplementary Table S1](#sup1){ref-type="supplementary-material"}). This list includes an overlapping set of 157 proteins in the cytoplasm, 132 in the nucleoplasm, and 89 in the chromatin fraction. Interestingly, gene ontology (GO) analysis showed that the cytoplasmic IDH1 interactome is significantly enriched in functional terms related to translation (*P* = 7.60E−46), while IDH1 interactomes in the nucleoplasm and chromatin are enriched in proteins related to mRNA processing such as RNA splicing and secondary structure unwinding (*P* ≤ 1.80E−06) ([Figure 1D](#f1){ref-type="fig"}). This result suggests potentially different functional roles of IDH1 in distinct subcellular contexts.

Interestingly, the heatmap view of IDH1 interactomes showed that RNase A treatment dramatically altered the nucleoplasmic interactome of IDH but had minor effects on the cytoplasmic and chromatin IDH1 interactomes ([Figure 1C](#f1){ref-type="fig"}; [Supplementary Table S1](#sup1){ref-type="supplementary-material"}). For example, upon RNase A treatment, 80% (106) out of 132 nucleoplasmic proteins failed to bind to IDH1, whereas 33% (29) of the 89 chromatin proteins and 39% (62) of the 157 cytoplasmic proteins showed reduced or abolished binding to IDH1. These results suggest the presence of both RNA-mediated and RNA-independent IDH1--protein interactions in different subcellular localizations.

IDH1 binds to the translation machinery {#sec4}
---------------------------------------

Intriguingly, the IDH1 interactomes in the cytoplasm are highly enriched in translation-related functions regardless of RNase A treatment ([Supplementary Figure S1A and B](#sup4){ref-type="supplementary-material"}). Among 157 proteins identified in the cytoplasmic IDH1 interactome without RNase treatment, 64 proteins are directly involved in translation, including 45 ribosomal proteins (20 and 25 from ribosomal small and large subunits, respectively); 3 initiation and elongation factors, EIF4E2, EIF4A1, and EEF1A1; and 16 translational regulators such as GNB2L1, PABPC1, PABPC4, and PCBP2 ([Figure 1E](#f1){ref-type="fig"} and [Table 1](#TB1){ref-type="table"}). These results suggest that IDH1 is linked to translation regulation.

We chose several candidate proteins that bind to IDH1 with different strengths and validated their physical associations with IDH1 by coIP and western blot analysis. The three ribosomal small and large subunits, RPS3, RPL3, and RPL7, exhibited strong affinity to IDH1 with high MS scores in the cytoplasmic interactomes (265, 329, and 209, respectively, in the absence of RNase A) ([Table 1](#TB1){ref-type="table"}). Two well-known translation regulators, EEF1A1 and PABPC1, showed high MS scores (249 and 692, respectively) ([@ref2]; [@ref6]). GNB2L1, also known as RACK1, has been reported as a component of the 40S ribosomal subunit which is involved in the initiation of ribosome quality control ([@ref3]; [@ref45]). EIF4E2 recognizes and binds the 7-methylguanosine-containing mRNA cap during translation initiation ([@ref26]; [@ref41]). GNB2L1 and EIF4E2 bind to IDH1 with relatively low MS scores of 45 and 35, respectively ([Table 1](#TB1){ref-type="table"}). FLAG-tagged IDH1, but not the negative control GFP, successfully pulled down the above seven proteins identified by TAP/MS in ESCs ([Figure 2A](#f2){ref-type="fig"}), while reciprocal coIP of HA-tagged EIF4E2 captured IDH1 ([Figure 2B](#f2){ref-type="fig"}; [Supplementary Figure S1C](#sup4){ref-type="supplementary-material"}), thus validating the IDH1 interactome.

Next, to ask whether IDH1 associates with polysome ribosomes that are engaged in active translation, we performed polysome fractionation and western blotting analysis. Indeed, IDH1 was robustly detected in the polysome fractions, similar to the positive control RPL27A, but in contrast to the chromatin regulator EZH2, which serves as the negative control ([Figure 2C](#f2){ref-type="fig"}). Co-migration of IDH1 with polysome ribosomes demonstrates that IDH1 directly interacts with the translation machinery.

###### 

IDH1-bound factors directly involved in translation.

  **Category**                                         **Gene symbol**   **Cytoplasm**   **Nucleoplasm**   **Chromatin**   **Fraction**                                     
  ---------------------------------------------------- ----------------- --------------- ----------------- --------------- -------------- ----- ----- ----- ---- ---------- ----------
  Ribosomal large subunits (21)                        RPS3              265             266                               185            82    7                           Cyto/Nuc
  RPS3A                                                211               177                                                                                     Cyto       
  RPS4X                                                208               160             5                                                                       Cyto       
  RPS2                                                 160               161                               42              29                                    Cyto/Nuc   
  RPS4L                                                239               96                                                                                      Cyto       
  RPS18                                                128               53              14                                                                      Cyto       
  RPS6                                                 105               82                                29              14                                    Cyto/Nuc   
  RPS8                                                 90                43                                10                                                    Cyto/Nuc   
  RPS9                                                 66                36                                                                                      Cyto       
  RPS13                                                48                60              3                                                                       Cyto       
  RPS23                                                45                26              2                                                                       Cyto       
  RPS14                                                35                7               5                                                                       Cyto       
  RPS16                                                32                                2                                                                       Cyto       
  RPS11                                                28                19              4                                                                       Cyto       
  RPS15A                                               23                                                                                                        Cyto       
  RPS24                                                22                29                                                                                      Cyto       
  RPS15                                                17                8                                                                                       Cyto       
  RPS26                                                14                23                                                                                      Cyto       
  RPS17                                                14                                2                                                                       Cyto       
  RPSA                                                 13                9                                                                                       Cyto       
  RPS27A                                                                                                   20              8              3     17    2     3    Nucl/Chr   
  Ribosomal large subunits (25)                        RPL3              329             139                               69             10                                Cyto/Nuc
  RPL4                                                 319               120                               22              26                                    Cyto/Nuc   
  RPL13                                                237               90                                64              54                   24    9          All        
  RPL6                                                 221               60                                63                                                    Cyto/Nuc   
  RPL7                                                 209               100                               39              24                                    Cyto/Nuc   
  RPLP0                                                135                                                                                                       Cyto       
  RPL7A                                                127               98                                13                                                    Cyto/Nuc   
  RPL27A                                               110               21                                                                                      Cyto       
  RPL8                                                 94                89                                62              10                                    Cyto/Nuc   
  RPL21                                                80                18                                12              85                                    Cyto/Nuc   
  RPL14                                                79                11                                                                                      Cyto       
  RPL27                                                64                4                                 38              35                                    Cyto/Nuc   
  RPL28                                                58                12                                                                                      Cyto       
  RPL24                                                56                12                                                                                      Cyto       
  RPL10L                                               55                32              8                                                                       Cyto       
  RPL13A                                               42                2                                                                                       Cyto       
  RPL18A                                               36                5                                 17              16                                    Cyto/Nuc   
  RPL26                                                34                49                                                                                      Cyto       
  RPL34                                                32                6                                                                                       Cyto       
  RPL23A                                               28                44              2                                                                       Cyto       
  RPL31                                                27                                                                                                        Cyto       
  RPL19                                                25                11                                                                                      Cyto       
  RPL17                                                23                21                                                                                      Cyto       
  RPL5                                                 21                186                               75                                                    Cyto/Nuc   
  RPL35A                                               11                17                                                                                      Cyto       
  Translational initiation & elongation factors (10)   EEF1A1            249             384                               787            200   149   120   31              All
  EIF4E2                                               35                16                                                                                      Cyto       
  EIF4A1                                               25                37                                277             7                    11               All        
  EIF2S3X                                                                                                  98                                   11               Nuc        
  EEF1G                                                                                                    73                                                    Nuc/Chr    
  EIF2S1                                                                                                   56                                                    Nuc        
  EEF2                                                                                                     21                                                    Nuc        
  EIF2S2                                                                                                   19                                                    Nuc        
  EIF3M                                                                                                    16                                                    Nuc        
  EIF3G                                                                                                    12                                                    Nuc        
  Translational regulators (17)                        YBX1              696             3                                                                                  Cyto
  PABPC1                                               692                                                                                                       Cyto       
  GAPDH                                                330               171             2                 556             133            14                     Cyto/Nuc   
  PABPC4                                               283                                                                                                       Cyto       
  DHX9                                                 168               48              2                 0               0              0     0     0     0    Cyto       
  IGF2BP1                                              111                                                                                                       Cyto       
  GIGYF2                                               61                                                                                                        Cyto       
  MOV10                                                57                                                                                                        Cyto       
  GNB2L1                                               45                18                                104             14                                    Cyto/Nuc   
  PCBP2                                                36                29                                208             7                                     Cyto/Nuc   
  DDX3X                                                32                5               2                 40              8              8     42    19    0    All        
  PCBP1                                                28                24                                145             7              2                      Cyto/Nuc   
  YTHDF2                                               26                12                                                                                      Cyto       
  TNRC6C                                               19                14                                                                                      Cyto       
  AGO2                                                 15                                2                                                                       Cyto       
  YTHDF1                                               13                                                                                                        Cyto       
  UBA52                                                                                                                                         17    2     3    Chr        

Proteins involved in the translation, including 46 ribosomal subunits and 27 translational regulators, are listed in [Table 1](#TB1){ref-type="table"}.

IDH1^−/−^ ESCs exhibit a modest decrease in translation initiation {#sec5}
------------------------------------------------------------------

To investigate the *in vivo* effect of IDH1 on translation, we sought to knock out IDH1 by utilizing the CRISPR/Cas9 system in ESCs. We used two small guide RNAs (sgRNAs) that flank a \~ 17-kb genomic region that covers the entire coding sequence (CDS) of the IDH1 gene in ESCs ([Figure 3A](#f3){ref-type="fig"}). Southern and western blot analyses confirmed that the two genomic IDH1 loci were successfully disrupted and its expression was abolished in homozygous ESC clones with biallelic deletions ([Figure 3B](#f3){ref-type="fig"} and [C](#f3){ref-type="fig"}). IDH1-null (IDH1^−/−^) ESCs showed no obvious defects in proliferation (data not shown), histone methylation, and m6A modification and RNA stability of selected IDH1-target transcripts ([Supplementary Figure S2A--F](#sup4){ref-type="supplementary-material"}). In addition, IDH1^−/−^ ESCs showed an insignificant tendency of downregulated protein synthesis as indicated by incorporation of O-propargyl-puromycin, which measures nascent polypeptides ([Supplementary Figure S2G and H](#sup4){ref-type="supplementary-material"}). Interestingly, IDH1^−/−^ ESCs exhibited an increase in the amount of the 80S monosome but a decrease in polysomes (≥ 4 ribosomes along an mRNA molecule) as shown by polysome fractionation ([Figure 3D](#f3){ref-type="fig"}).

![IDH1 binds to the translation machinery. (**A**) Anti-FLAG IP results using cell lysates of ESCs co-expressing FLAG-tagged IDH1 or GFP and HA-tagged selected proteins (RPS3, RPL3, RPL7, EEF1A1, EIF4E2, GNB2L1, and PABPC1). Anti-HA antibody was used for western blot analysis. (**B**) The results of reciprocal coIPs. The antibody of HA tag was used for immunoprecipitation, and IgG was used as negative control. IDH1 was detected by western blotting using antibody of FLAG. (**C**) Polysome fractionation of ESCs showing that IDH1 co-migrates with active translational machinery. EZH2 and RPL27 were used as negative and positive controls, respectively.](mjz082f2){#f2}

![Deletion of IDH1 in ESCs moderately affects translation of IDH1-target RNAs. (**A**) Schematic diagram of the IDH1 knockout strategy. The small guide RNAs used to create the IDH1 deletion are highlighted with red arrows. The DNA probe used for Southern blot is labeled in blue. (**B**) Results of Southern blot to validate IDH1^−/−^ ESCs. (**C**) Results of western blot to validate IDH1^−/−^ ESCs. (**D**) Results of polysome fractionation using IDH1^−/−^ and wild-type (WT) ESCs. (**E**) Results of metagene analysis to reveal the distribution of average ribosome density from IDH1-binding transcripts aligned at start codons for WT (black line) and IDH1^−/−^ (red line) ESCs. Ribosome footprint density was normalized by the mean density of codons across the CDS, excluding the first 30 codons due to the accumulation of ribosomes. All normalized ribosome footprint density was averaged across the replicates. The results were showed based on nucleotide windows range from 50 nucleotides upstream of start codons to 100 nucleotides downstream of start codons. *P*-value of the change at start codon was shown, *P*-value \<  2.2E−16. The zoom-in result was shown in panel (ii) using nucleotide windows range from 3 nucleotides upstream of start codons to 21 nucleotides downstream of start codons. (**F**) Ribosome footprint density profiles of IDH1 targets (i) and nontargets (ii) aligned at start codons based on codon windows across the transcripts. (**G**) Results of polysome profiling. RNAs were grouped into two categories: those bound by IDH1 (targets) and the others (nontargets) (FPKM ≥1). Target RNAs were subdivided based on the locations of IDH1-binding peaks within the mRNA transcripts. Data are shown as median. \*\*\*\**P*-value \<  0.0001. (**H**) Genome browser views of polysome profiling signals along IDH1-target transcripts.](mjz082f3){#f3}

To gain further molecular insights, we performed ribosome profiling, which quantifies ribosome-protected RNA fragments engaged in protein synthesis ([@ref24]; [@ref23]). IDH1^−/−^ and wild-type ESCs detected a total of \~ 8028 RNA transcripts with a pattern of 3-base codon periodicity, confirming successful capture of the reads from translating 80S ribosomes in proper open reading frames ([Supplementary Figure S3A--D](#sup4){ref-type="supplementary-material"} and [Table S3](#sup3){ref-type="supplementary-material"}). IDH1^−/−^ ESCs showed no obvious differences in total ribosome-bound RNA reads and averaged ribosome densities on a transcript normalized to RNA expression ([Supplementary Figure S3E and F](#sup4){ref-type="supplementary-material"}).

Interestingly, metagene analysis of reads distribution along the gene body showed a subtle increase of ribosome density at the start codon in all ribosome-protected transcripts in IDH^−/−^ ESCs (data not shown). To reveal IDH1-dependent changes in translation, we classified ribosome-protected transcripts into the target and nontarget of IDH1 based on IDH1 ^FBio^CLIP-seq ([@ref32]). Both target and nontarget mRNAs of IDH1 showed modest yet significant increases of ribosome density at the start codon ([Figure 3E](#f3){ref-type="fig"} and [F](#f3){ref-type="fig"}).

Notably, IDH1-target RNA exhibited slight decrease in ribosome densities along the transcript immediately downstream of the start codon, while this effect was less obvious for nontargets of IDH1 ([Figure 3E](#f3){ref-type="fig"} and [F](#f3){ref-type="fig"}). No obvious changes were observed around the stop codon ([Supplementary Figure S3G](#sup4){ref-type="supplementary-material"}). The observation that the 80S ribosome got slightly trapped at the translation start site in IDH^−/−^ ESCs suggests a fine-tuning function of IDH1 in promoting translation initiation.

Decreased polysome RNA in IDH1^−/−^ ESCs {#sec6}
----------------------------------------

Next, we sought to examine the amount of actively translated RNA transcripts that are present in polysome fractions that consist of RNA transcripts occupied by multiple (≥4) ribosomes. To characterize molecular effects of knockout of IDH1 on translating individual transcripts, we then collected and profiled actively translating polyA RNAs in polysome fractions (≥4 ribosomes). We performed three biological replicates of polysome RNA-sequencing (RNA-seq) using two independent IDH1^−/−^ ESC clones and also did RNA-seq analysis of the input mRNA that was collected prior to polysome fractionation. To minimize a potential influence by differences in levels of RNA transcripts in wild-type and IDH1^−/−^ ESCs, we first normalized signals of polysome RNA-seq to the input mRNA and then calculated the ratios of normalized polysome signals of individual transcripts in IDH1^−/−^ ESCs to those in wild-type ESCs. In such a way, the relative ratios of RNA associated with polysomes in IDH1^−/−^ and wild-type ESCs represent direct changes in translation efficiency, rather than mRNA expression.

In total, we detected 5597 transcripts that are associated with actively translating polysomes with FPKM ≥1 (fragments per million total exon-mapped fragments). We classified these polysome-bound transcripts into the set of IDH1-target RNA (1303 identified by IDH1 ^FBio^CLIP-seq) and the set of nontarget RNA comprising the remaining 4294 transcripts ([Supplementary Table S2](#sup2){ref-type="supplementary-material"}). Interestingly, by comparing IDH1^−/−^ to wild-type ESCs, the global translation efficiency of IDH1-target RNAs exhibited modest yet significant decreases with a mean fold of change of 0.84 (*P* \< 0.01) compared to that of the nontarget group (mean fold of change: 1.00) ([Figure 3G](#f3){ref-type="fig"} and [H](#f3){ref-type="fig"}).

We further classified polysome-associated IDH1-target RNAs into three subsets based on the localization of IDH1 ^FBio^CLIP-seq peaks. The set of 309 UTR-target RNAs (with CLIP signals in the UTR and perhaps other regions) exhibited the most significant decreases in translation efficiency upon IDH1 deletion with a mean fold of change of 0.80 (*P* \< 0.01) ([Figure 3G](#f3){ref-type="fig"}). The set of 709 CDS-target RNAs (with CLIP signals detected only in the CDS) also exhibited a significant decrease in translation efficiency with a mean fold of change of 0.85 (*P* \< 0.01), whereas the set of 41 intronic targets (with CLIP signals exclusively detected in the introns) showed no change ([Figure 3G](#f3){ref-type="fig"}). Taken these results together, IDH1 deletion in ESCs globally downregulated the amounts of IDH1-target RNA transcripts that are associated with actively translating polysomes, congruent with the proposed role of IDH1 in promoting translation.

Tethering IDH1 promotes translation of the luciferase reporter {#sec7}
--------------------------------------------------------------

To test a role of IDH1 in regulating translation, we tethered IDH1 to an mRNA encoding the Renilla luciferase reporter by fusing IDH1 with the bacteriophage MS2 coat protein (MS2CP), which recognizes a sequence tag with 24 copies of the MS2 element (24× MS2) inserted in the 3′ untranslated region of luciferase reporter (denoted as RLuc-MS2) ([Figure 4A](#f4){ref-type="fig"}). Co-transfection of IDH1--MS2CP fusion protein with the RLuc-MS2 reporter in 293T cells significantly enhanced the luciferase reporter activity by \~ 4-fold, compared to the negative controls of MS2CP alone or MS2CP fused to GAL4 DNA-binding domain ([Figure 4B](#f4){ref-type="fig"}). By contrast, IDH1 failed to affect the luciferase activity in a control reporter lacking the 24× MS2 cassette ([Figure 4A](#f4){ref-type="fig"} and [B](#f4){ref-type="fig"}), arguing against a possible effect of IDH1 overexpression in promoting luciferase activity. In mouse ESCs, tethering IDH1 to the RLuc-MS2 reporter also significantly increased the luciferase activity ([Figure 4C](#f4){ref-type="fig"}), suggesting a conserved phenomenon in both mouse and human cells. Notably, tethering IDH1 did not change the steady-state abundance and stability of the luciferase mRNA ([Supplementary Figure S4A and B](#sup4){ref-type="supplementary-material"}). Based on these observations, we concluded that IDH1 promotes translation of the reporter mRNA without affecting RNA synthesis and turnover. Moreover, we found that tethering IDH1 to the 3′ UTR than to the 5′ UTR appeared to be more effectively to promote the reporter activity ([Supplementary Figure S4C](#sup4){ref-type="supplementary-material"}).

![IDH1 promotes cap-dependent translation initiation independently of its catalytic activity. (**A**) Schematic diagrams of the tethering assays are shown in panels (i) and (ii). Panel (i) shows the assay in which IDH1 is recruited to the 3′ UTR of Renilla luciferase mRNA via the MS2 system, whereas panel (ii) is the negative control in which IDH1 cannot be recruited to the mRNA. (**B**) Results of luciferase reporter-based tethering assays in 293T cells. Data are shown as mean ± SD; *n* = 3; \**P* \< 0.01. (**C**) Results of the tethering assay in ESCs. Data are shown as mean ± SD; *n* = 3; \**P* \< 0.01. (**D**) Cartoons showing the IDH1 truncations used for tethering assays. (**E**) Results of tethering assays using IDH1 truncations and variants. Data are shown as mean ± SD; *n* ≥ 2; \**P* \< 0.01. (**F**) Schematic diagram of the tethering assays using different IRESs in the luciferase reporter system. (**G**) Results of tethering assays using different translation systems including canonical cap-dependent translation and IRES (CrPV, HCV, and EMCV)-driven translation. Data are shown as mean ± SD; *n* = 3; \**P* \< 0.01.](mjz082f4){#f4}

Asymmetric homodimerization of IDH1 forms two deep clefts of the catalytic sites ([@ref51]; [@ref52]). To test the domain(s) required for IDH1 activity in promoting translation, we generated a series of truncation mutants, including the amino-terminal big domain (aa 1--103), the carboxyl-terminal domain lacking the first big domain (aa 104--414), and the small domains in the middle (aa 104--285 and aa 136--285) ([Figure 4D](#f4){ref-type="fig"}). In IDH1^−/−^ ESCs lacking IDH1, tethering all truncation mutants of IDH1 to the reporter failed to promote luciferase activity ([Figure 4E](#f4){ref-type="fig"}), indicating that an intact protein structure is required for IDH1's activity. Intriguingly, in 293T cells expressing endogenous IDH1, three mutants (aa 1--103, aa 104--414, and aa 104--285) increased luciferase activity at levels comparable to wild-type IDH1 ([Supplementary Figure S4D](#sup4){ref-type="supplementary-material"}). We reasoned that these truncated IDH proteins may form asymmetric dimers with and recruit endogenous IDH1 to the reporter, thereby leading to enhanced luciferase activity in 293T cells. This result suggests that IDH1 may enhance translation in the form of a homodimer or self-interacting complex in cells.

To study the effect of IDH1 enzymatic activity on translation, we mutated a number of key residues that are known to be involved in IDH1's substrate binding and catalytic activity. For example, the cancer-associated R132H mutation affects the R132 residue, which binds the substrate isocitrate ([@ref51]). Another active site residue H315, which binds NADP^+^, was mutated to alanine. Interestingly, all mutations in IDH1 catalytic sites, including R132H, T77A, Y139A, D252A, and H309A, were able to promote luciferase activity at levels (\~4-fold increase) similar to that of wild-type IDH1 in the reporter tethering assay conducted in IDH1^−/−^ ESCs ([Figure 4B--E](#f4){ref-type="fig"}; [Supplementary Figure S4E](#sup4){ref-type="supplementary-material"}). By contrast, H315A mutation that affects IDH1 binding to NADP^+^ exhibited dramatically reduced activity (\~2-fold increase) ([Figure 4E](#f4){ref-type="fig"}). These results suggest that IDH1 promotes translation independently of its catalytic activity but may involve its binding to NADP^+^.

IDH1 enhances the initiation of cap-dependent translation {#sec8}
---------------------------------------------------------

Protein synthesis in eukaryotes is classified as cap-dependent and cap-independent based on the mechanisms of translation initiation. Translation initiation in eukaryotes requires the ordered assembly of ribosomal pre-initiation complexes ([@ref25]; [@ref22]). For cap-dependent translation, the EIF4F complex, composed of eukaryotic translation initiation factors EIF4A, B, E, and G, first binds to the 7-methylguanosine cap structure at the 5′ end of the mRNA. Association of EIF4E with the EIF4F complex is the rate-limiting step in translation initiation. The initial binding of the EIF4F complex recruits 40S ribosome to the 5′-cap structure and scans to the initiation codon. The 60S ribosomal subunit subsequently joins to form an active 80S ribosome for productive translation ([@ref22]). Renilla luciferase in the RLuc-MS2 reporter undergoes cap-dependent translation with the canonical initiation step ([Figure 4A--E](#f4){ref-type="fig"}).

For cap-independent translation, the initiation machinery is recruited, assembled, and activated by structured RNA sequences, named internal ribosome entry sites (IRESs), in the vicinity of the initiation codon ([@ref14]; [@ref29]). To further understand the mechanism of IDH1-mediated translation promotion, we employed three different IRES reporters that allowed us to interrogate which steps and initiation factors are responsible for promoting translation. The cricket paralysis virus (CrPV) IRES bypasses the requirement of initiation factors and initiates translation from the A site of the ribosome using a eukaryotic translation elongation factor ([@ref29]; [@ref36]). The hepatitis C virus (HCV) IRES bypasses the requirement of the EIF4F complex but requires eukaryotic translation initiation factors 2, 3, and 5 (EIF2, EIF3, and EIF5) and Met-tRNAi. In comparison, the encepha lomyocarditis virus (EMCV) IRES requires all initiation factors except for the cap-binding factor EIF4E---a rate-limiting component for the assembly of the EIF4F complex ([@ref14]; [@ref29]; [@ref36]).

IDH1 failed to promote translation in all three IRES reporters (CrPV, HCV, and EMCV) ([Figure 4F](#f4){ref-type="fig"} and [G](#f4){ref-type="fig"}). These results indicate that IDH1 facilitates the translation initiation step in a manner dependent on the EIF4F complex, particularly on EIF4E. Importantly, we have shown that EIF4E2, a family member of EIF4E, physically associates with IDH1, as revealed in the IDH1--protein interactome and confirmed by reciprocal coIP ([Figures 1E](#f1){ref-type="fig"}, [2A](#f2){ref-type="fig"} and [B](#f2){ref-type="fig"}; [Supplementary Figure S1C](#sup4){ref-type="supplementary-material"}; [Table 1](#TB1){ref-type="table"}). The negligible effect of IDH1 on the HCV IRES reporter is congruent with the finding that EIF2, 3, and 5 were not detected in the cytoplasmic IDH1 interactome. Together, these results suggest that IDH1 promotes cap-dependent translation initiation likely via the EIF4F complex.

Discussion {#sec9}
==========

Translation is one of the most energy-consuming processes in cells, and its dysregulation usually causes neoplastic diseases ([@ref4]; [@ref46]; [@ref39]). Here, we systematically surveyed the IDH1-bound proteomes in ESCs. Strikingly, of \~ 285 proteins identified with diverse functions and subcellular localizations, \~ 64 proteins including ribosomal components and translational regulators are significantly enriched in the cytoplasmic IDH1 interactome. In addition, IDH1 co-migrates with the translation machinery in polysomes associated with active translation. Importantly, IDH1^−/−^ ESCs exhibited globally stalled 80S ribosomes at the translation start codon and specific decreases of polysome-associated RNA transcripts that are preferentially bound by IDH1. Direct tethering of IDH1 to the luciferase mRNA facilitated reporter translation without changing RNA abundance and stability. By employing various IRES reporters, we further showed that IDH1 promotes cap-dependent translation initiation likely via the EIF4F complex, and this function is independent of the catalytic activity of IDH1. Based on these lines of evidence, we propose that IDH1 interacts with the translation machinery and fine-tunes mRNA translation ([Figure 5](#f5){ref-type="fig"}).

![Model of the role of IDH1 in translational modulation of mRNA targets IDH1 has been found to bind translation factors such as the EIF4E2, EEF1A1, and components of ribosomes. The fact that IDH1 co-migrates with polysome fractions further indicates that IDH1 interacts with the active translational machinery. Importantly, IDH1 specifically binds to AU- or GA-rich motifs on mRNA transcripts that encode proteins involved in epigenetic regulation and cell cycle. Deletion of IDH1 in ESCs moderately attenuated global translation efficiency of its target RNA transcripts, as demonstrated by decreased numbers of RNA transcripts that are actively associated with polysome fractions, and increased ribosomal occupancy at start codon on RNA. Tethering IDH1 to mRNA via the MS2-MBP system facilitated translation without changing mRNA abundance and stability. Deciphering the mechanism of IDH1-mediated translational promotion by employing different IRES reporters suggests that IDH1 regulates the initiation step of cap-dependent translation via the EIF4F complex, and this function is independent of the wild-type catalytic activity of IDH1.](mjz082f5){#f5}

Although the *in vivo* effects upon loss of IDH1 were very subtle, attenuated translation could be robustly detected by multiple complimentary approaches. First, polysome fractionation indicated an increase of the 80S monosomes and a decrease in polysomes in IDH1^−/−^ ESCs ([Figure 3D](#f3){ref-type="fig"}). Second, ribosome profiling revealed accompanied increases at the translation initiation site and decreases of ribosome-protected RNA immediately downstream along the transcript in IDH1^−/−^ ESCs ([Figure 3E](#f3){ref-type="fig"} and [F](#f3){ref-type="fig"}). Third, IDH1-target RNA transcripts exhibited specific downregulation in association with actively translating polysomes in IDH1^−/−^ ESCs as shown by polysome RNA-seq ([Figure 3G](#f3){ref-type="fig"} and [H](#f3){ref-type="fig"}). These lines of evidence demonstrate that IDH1 influences mRNA translation *in vivo* as a fine-tuner rather than being a switch-like translation activator. We propose that IDH1 may regulate cap-dependent translation initiation by modulating the dwelling and scanning time of the 80S ribosome at the translation start codon of target mRNAs of IDH1. However, we cannot rule out a potential role of IDH1 in promoting translation elongation, as it interacts with elongation regulators such as EEF1A ([Figures 1E](#f1){ref-type="fig"} and [2A](#f2){ref-type="fig"}). Future studies should fully define the exact step and mechanism by which IDH1 promotes translation.

Intriguingly, IDH1 interactomes vary in subcellular contexts. The cytoplasmic IDH1 interactome is enriched with translation factors, whereas proteins involved in RNA splicing and processing are enriched in the nucleoplasmic and chromatin IDH1 interactomes. For example, proteins in the catenin family (i.e. CTNNB1, CTNNA1/2, and CTNND1), histones, components of spliceosome (e.g. SRSF1, SRSF2, and SRSF7), and epigenetic regulators (e.g. JARID2, EP400, and RUVBL1/2) were only detected in the nucleoplasmic and chromatin fractions ([Supplementary Table S1](#sup1){ref-type="supplementary-material"}). The nucleoplasmic interactome of IDH1 was more sensitive to RNase A treatment than cytosolic and chromatin interactomes, likely reflecting different functional roles of IDH1 in an RNA-regulated manner. It was reported that metabolic enzyme PKM2 has multifaceted functions, which largely depend on its subcellular localization ([@ref53]; [@ref1]; [@ref19]). Our results suggest that IDH1, like PKM2, may have specific functions in different subcellular compartments.

Metabolic enzymes like GAPDH and PKM2 have been implicated in regulating the stability and translation of RNA transcripts to which they bind ([@ref40]; [@ref55]; [@ref24]; [@ref7]; [@ref15]). Our work supports the notion that metabolic enzymes may serve as a regulatory link to mediate cross-talks between posttranscriptional gene expression and intermediary metabolism ([@ref20]; [@ref21]). Whether and how IDH1 functions in translational regulation in other cellular contexts, such as nutrient deprivation induced stress, and in relevant cancer or somatic cell types, will be addressed in future studies.

In summary, our study provides a framework for future exploration of the mechanisms and functions of IDH1-mediated cellular processes. Identification of the noncanonical function of IDH1 in translation regulation may help the future development of therapeutic strategies for clinical use.

Materials and methods {#sec10}
=====================

Cell culture {#sec11}
------------

Mouse ESCs were maintained in complete ESC culture medium: Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 15% heat-inactivated fetal calf serum (FCS), 1% nucleotide mix (100× stock, Millipore), Penicillin--Streptomycin Solution (100× stock, Life Technologies), 2 mM Glutamax (100× Life Technology), 0.1 mM nonessential amino acids, 0.1 mM 2-mercaptoethanol, and supplied with 1000 U/ml recombinant leukemia inhibitory factor (LIF, Millipore). ESCs were cultured on plates which were pre-coated with 0.1% gelatin. The HEK 293T cells were cultured in medium containing DMEM, 10% FCS, 1× Penicillin--Streptomycin Solution.

Construction of IDH1^−/−^ ESCs using the CRISPR/Cas9 system {#sec12}
-----------------------------------------------------------

Deletion of Idh1 in ESCs was performed following the method described previously ([@ref35]). Briefly, plasmids expressing Cas9 (Addgene ID 44758; Pst1374-N-NLS-FLAG-linker-Cas9) and two sgRNAs ('pGL3-U6-sgRNA', 5′-CTGCATTTCTGGAAAGAAAG-3′ and 5′-GGGCTTAGAATGAGTCTTTG-3′) flanking the genomic regions to be deleted (the full-length CDS region of IDH1, \~17 kb) were co-transfected into ESCs. ESCs were selected by puromycin (for Cas9-expressing cells) 24 h posttransfection for 2 days. After confirming deletion in the mixture of cells, ESCs were plated at low density in 10-cm plates, and clones were picked after selection for 1 week. Individual ESC clones were picked, expanded, and validated by PCR genotyping, Southern blotting, and immunoblotting.

Transfection {#sec13}
------------

Lipofectamine 3000 was used for transfection. For 293T cells, transfection was carried out according to the manufacturer's instructions (Life Technology). For ESCs, the plasmids and lipofectamine 3000 were prepared according to the manufacturer's instructions and were added into the floating ESCs resuspended in complete ESC culture medium during passage. Then, the ESCs were placed in a gelatin-coated plate for further studies.

Subcellular fractionation and TAP/MS {#sec14}
------------------------------------

ESCs from ten 15-cm plates were digested by trypsin and harvested by centrifugation at 1500 rpm in 15-ml conical tubes. The cell pellet was rapidly resuspended in 5--10 times of the pellet volume of cold Hypotonic Buffer A (20 mM HEPES, pH 7.5, 10 mM KCl, 1.5 mM MgCl~2~, 1 mM EDTA, 0.2% NP-40, 10% glycerol, and freshly added protein inhibitors DTT and PMSF) and spun gently and quickly at 1300 *g* for 3 min at 4°C. The pellet was resuspended using \~2.5 times of the pellet volume of cold Hypotonic Buffer A and pipetted roughly. The resuspended cells were transferred to a 15-ml Dounce homogenizer and homogenized up and down slowly 10 times. The homogenate was centrifuged at 14000 rpm for 20 sec at 4°C, and the supernatant was collected as the cytoplasmic fraction. The pellet was resuspended using ice-cold high-salt buffer B (20 mM Tris--HCl, pH 7.5, 10 mM KCl, 350 mM NaCl, 1.5 mM MgCl~2~, 1 mM EDTA, 20% glycerol, and freshly added protease inhibitors DTT and PMSF), rotated for 30 min at 4°C, and centrifuged at 14000 rpm for 20 min at 4°C. The supernatant was collected as the nucleoplasmic fraction. The pellet was resuspended using DNaseI digestion buffer (20 mM HEPES, pH 7.5, 15 mM NaCl, 6 mM MgCl~2~, 1 mM CaCl~2~, 10% glycerol, freshly added protease inhibitors DTT and PMSF, and 5 U/ml DNase I) and rotated for 30 min at room temperature (RT). This was followed by addition of an equal volume of high-salt buffer and incubation for another 15 min. The mixture was centrifuged at 14000 rpm for 20 min at 4°C, and the supernatant was collected as the chromatin fraction. An equal volume of dilution buffer (20 mM Tris-Cl, pH 7.5, 15 mM NaCl, 0.3% NP-40, 1 mM EDTA, pH 8.0, and 10% glycerol) was added into the nucleoplasm and chromatin fractions. All the fractions were used for TAP/MS as previously described ([@ref27]).

Polysome fractionation and profiling {#sec15}
------------------------------------

ESCs from two 15-cm plates were used for polysome fractionation and profiling, which were performed as previously described ([@ref12]). Briefly, ESCs were treated with cycloheximide (CHX) at 0.1 mg/ml for 5 min, pelleted and lysed on ice. The cell lysate was loaded onto a 10%--50% (*w/v*) sucrose gradient and centrifuged at 39000 rpm for 1.5--2 h at 4°C. Then the samples were fractionated and analyzed using aPiston Gradient Fractionator (BioComp Instruments, Inc.) and a Fraction Collector (GILSON, Inc.). The samples from each fraction were collected, and mRNA was extracted for RNA sequencing or for western blotting.

Ribosome profiling {#sec16}
------------------

ESCs from two 15-cm plates were used for ribosome profiling. The procedure was followed as previously described ([@ref24]). Briefly, ESCs were treated with CHX at 0.1 mg/ml for 5 min before being harvested and lysed. The lysates were treated with RNase I for 45 min at room temperature, and the nuclease digestion was stopped with 200 U SUPERase-In. Mono-ribosomal fractions were separated and pelleted using sucrose cushion by centrifugation at 70000 rpm at 4°C for 4 h. RNA fragments were extracted from ribosomal pellets using Trizol reagent and purified on a 15% (*w/v*) polyacrylamide TBE-urea gel. Then, the purified RNA fragments were used for library construction and rRNA depletion for RNA sequencing.

Luciferase reporter assay {#sec17}
-------------------------

The luciferase reporter assay was carried out according to the manufacturer's instructions (Promega, E1910).
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